
Opinion|Videos|November 25, 2024
Episode 2: Incidence of ESR1 mutations and best practices for testing
Along with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations are commonly observed in hormone receptor-positive breast cancer after prolonged endocrine therapy, and emphasizes the importance of molecular testing for ESR1 mutations at both the initial diagnosis of MBC and at each subsequent progression using liquid biopsy assays.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5
















